 MESSAGE FROM THE DIRECTOR
Stan Gerson, MD
Director, Case CCC
Case CCC Strategic Plan 2012-2018
We have revised the Case CCC Strategic Plan 2012-2018 through consultation with the Executive Committee and Program Leaders. The revised Strategic Plan contains updates for each scientific program and the initiatives in genomics, breast cancer and brain tumors. We have also provided more focus on our disease-based efforts and the integration of nano medicine, imaging and bioinformatics.
We plan on posting the Strategic Plan on the Cancer Center website in two weeks, and will also have it available at the site visit on October 23. With this in mind, please review the Strategic Plan and send me your feedback within the next weeks.
Also, as a reminder as we prepare for the site visit, please keep your Program Leader up to date on recent grants and publications.
CASE CCC IN THE NEWS
Broadview Heights Man Overcomes Disease, Continues to Live Life to the Fullest
Plain Dealer - Sep 18, 2012
Not only is his illness under control, but it has become nearly undetectable since he began seeing myeloma specialist Dr. Frederick Reu at the ...
Study shows vitamin E may decrease cancer risk in Cowden ...
Medical Xpress-Sep 17, 2012
... in the succinate dehydrogenase (SDH) genes may be responsible for cancer development, according to research by Charis Eng, M.D., Ph.D., ...
The Widow's Doctor Visit
New York Times (blog)-Sep 12, 2012
By MIKKAEL A. SEKERES, M.D.. Brian Stauffer. I walked into the examination room and saw her sitting there, her arm around her 10-year-old ...
ANNOUNCEMENTS
Case CCC American Cancer Society Institutional Research Grant Pilot Awards
Congratulations to the recent recipients of the Case CCC American Cancer Society Institutional Research Grant pilot awards:
- Medhat Askar, MD, PhD: The Impact of MHC Class I Chain-Related Gene A (MICA) Donor-Recipient Mismatches and MICA-129 Polymorphism On Unrelated Donor Hematopoietic Stem Cell Transplants (HSCT) for Hematological Malignancies
- Paolo Caimi, MD: Finding new predictive and prognostic factors in Chronic Lymphocytic Leukemia: High - resolution flow cytometry analysis of CLL samples from the Eastern Cooperative Oncology Group Randomized Clinical Trial E2997
- Hannah Gilmore, MD: Ex vivo expansion of cancer stem cells (CSCs) in breast malignancies using mammospheres
- Justin D. Lathia, PhD: Interrogating cell communication in the Glioblastoma cellular hierarchy
- Mary M. Step, PhD: Feasibility of a Team Approach for Discussing Prognosis and Treatment Goals (T-PAT) During Advanced Breast Cancer
- Ramon V. Tiu, MD: In-vitro and In-vivo effects of spliceosome inhibitors/ modulators, hypomethylating agents, growth factors and immunomodulatory agents in SF3B1 mutant primary bone marrow cells and in mouse models of Sf3b1
- Jennifer Yu, MD, PhD: Hyperthermia Sensitizes Glioblastoma Initiating Cells to Radiation Via Downregulation of AKT
These funds are designed to provide seed money to support junior faculty members with an interest in cancer research who do not have national grant support of their own.
FUNDING OPPORTUNITIES
Association for Research of Childhood Cancer
The Association for Research of Childhood Cancer is accepting applications for its grant award program. The purpose of these awards are to provide funding for basic science and clinical projects related to the goal of advancing knowledge in pediatric and adolescent cancers.
Deadline: January 1, 2013
NCI CANCER BULLETIN
September 18, 2012
News
Featured Article: Lung Cancer Genome Surveys Find Many Potential Drug Targets
Diagnostic Radiation Exposure May Raise Breast Cancer Risk in Some BRCA1/2 Mutation Carriers
New Drug Improves Survival in Patients with Advanced Lung Cancer
Drug Targeting Tumor Suppressor Shows Promise in First Human Study
Study Reveals How Breast Cancer Spreads to Lymph Nodes
Also in the Journals: Smoky Coal Associated with Increased Risk of Lung Cancer in Rural China
Also in the Journals: Best Practices Can Reduce Central-Line Infections in Children with Cancer
Commentary
Guest Commentary by Assistant Secretary for Health Dr. Howard Koh: Changing Social Norms about Tobacco Use, One Campus at a Time
A Conversation with Dr. John Stamatoyannopoulos about ENCODE and Cancer Research
In Depth
Building a Biobank to Explore Mysteries of the Genome
Singled Out: Researchers Look to Single Cells for Cancer Insights
Featured Clinical Trial: Treating KSHV-Associated Multicentric Castleman Disease
Updates
AHRQ Update
FDA Update
Notes
| EVENTS
September 24
Hematology/Oncology Special Conference
Ronald Maggiore, MD
Clinical Fellow, Div. of Hem/Onc
University of Chicago
Topic: Geriatric Oncology Approaches in Head/Neck Cancer
12 pm Wearn 137
Pathology Research Seminar Series
Chao Feng
Schmaier Lab, Div. of Hem/Onc
CWRU/UH
Topic: TBD
12 pm WRB 1-413
Physiology and Biophysics Seminar
Eric Delpire, PhD
Professor, Anesthesiology and Molecular Physiology & Biophysics
Vanderbilt University
Topic: Ste20 and WNK kinases in the regulation of Na+-(K+)-Cl- transport
4 pm SOM / Robbins Building, E-501
September 25
Immunology Seminar Series
Cheng-Kui Qu, MD, PhD
Associate Professor, Div. of Hem/Onc
CWRU/UH
Topic: Bioenergetic Regulation of Hematopoietic Stem Cell Differentiation
12 pm WRB 1-413
Pharmacology Invited Seminar
Steven Ludtke, PhD
Associate Professor, Biochemistry and Molecular Biology
Baylor College
Topic: Macromolecular Motion and Variability Via CryoEM and CryoET
12 pm Webster Conference Rm, W331
Pharmacology Invited Seminar
David Goldstein, PhD
Director, Center for Human Genome Variation
The Richard and Pat Johnson Distinguished University Professor
Duke University
Topic: Complete Sequencing and Human Disease: A Genetic Approach to Genomics
1 pm Webster Conference Rm, W331
September 26
Hematology and Oncology Division Research Conference canceled
Immunology Invited Speaker Seminar Series
Pushpa Pandiyan, PhD
Assistant Professor, Biological Sciences
CWRU
Topic: Suppressive and Non-Suppresive Functions of Foxp3+ Regulatory T Cells
12 pm NC1-202 Cleveland Clinic
Innovative Science Discussion Group
Topic: Discovery of New Mechanism of Oncogenic Mutation
12:15 pm WRB 3-136
September 27
September 28
Hematology/Oncology Fellows Conference/Curriculum Series
Hillard Lazarus, MD
Professor, Div. of Hem/Onc
CWRU/UH
AND
Andy Parchman, MD
Fellow, Div. of Hem/Onc
CWRU/UH
Topic: Core Binding Factor Acute Myeloid Leukemia
8 am Wearn 137
Cell Biology Seminar Series
Dean Tang, MD, PhD
Professor, Carcinogenesis
University of Texas MD Anderson Cancer Center
Topic: Understanding the Cellular Heterogeneity of Prostate Cancer
10 am NC1-202 Cleveland Clinic
Cancer Center Seminar Series
Yogen Saunthararajah, MD
Associate Professor, Hematologic Oncology and Blood Disorders
CWRU/Cleveland Clinic
Topic: Genetic-Epigenetic Interactions in Oncogenesis and Clinical Translation into Non-Cytotoxic Epigenetic Therapy
12 pm Frohring Auditorium – BRB 105
Cancer Center Research in Progress
Hong Zheng, PhD
Postdoctoral Scholar, Qu Lab, Div. of Hem/Onc
CWRU/UH
Topic: An Activating Mutation of Protein Tyrosine Phosphatase Ptpn11 (Shp2) in the Hematopoietic Microenvironment Induces Myeloproliferative Disorder
4 pm WRB 3-136
Case CCC Calendar
LRI Calendar
UPCOMING CANCER CENTER SYMPOSIUMS & EVENTS
National GvHD Health Symposium
November 2
Embassy Suites Cleveland-Rockside
Details
Registration
ADDITIONAL UPCOMING SEMINARS & EVENTS
Ninth International Conference of the Society for Integrative Oncology
October 8-10
Albuquerque, NM
Details
Biennial Science of Global Prostate Cancer Disparities conference
November 1-4
Nassau, The Bahamas
Details
The Cancer Genome Atlas 2nd Annual Scientific Symposium: Enabling Cancer Research Through TCGA
November 27-28
Crystal City, Virginia
Details
Deadline to submit abstracts: October 5
American Society of Hematology (ASH) Annual Meeting
December 8-11
Atlanta, Georgia
Details
Pacific Symposium on Biocomputing 2013
January 3-7, 2013
Fairmont Orchid, Hawaii
Details
|
